Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12793245 | 0.87 | POLB (0.88) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL29687970 | 0.85 | POLB (0.67) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL1987080 | 0.84 | USP2 (0.70) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL5804200 | 0.82 | USP2 (0.74) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL2798288 | 0.82 | USP2 (0.74) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL4811982 | 0.82 | POLB (0.63) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL7267448 | 0.82 | POLB (0.63) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL3591766 | 0.82 | POLB (0.63) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL12793258 | 0.82 | POLB (1.00) | POLBLMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL12793309 | 0.81 | POLB (0.67) | POLBLMNASMN1; SMN2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4125861-A2 | PROTEIN-PROTEIN INTERACTION STABILIZERS | The Regents of the University of California (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-105008350-B | Antiviral compound | 弗·哈夫曼-拉罗切有限公司 | 2018-05-08 | — | — | CN | disclosed |
| EP-2964637-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9428469-B2 | Antiviral compounds | HOFFMANN-LA ROCHE (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160009666-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2016-01-14 | — | — | US | disclosed |
| EP-2964637-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| CN-105008350-A | Antiviral compounds | HOFFMANN LA ROCHE HOFFMANN LA ROCHE | 2015-10-28 | — | — | CN | disclosed |
| WO-2014135422-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006124692-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006093518-A2 | THIENYL COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | APATH, LLC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009666-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | POLB 863/4885LMNA 3788/4885SMN1; SMN2 2807/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | POLB 1976/4885LMNA 3216/4885SMN1; SMN2 1311/4885 |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | HSPBP1, HSPA8, HSPH1 | POLB 3568/4885LMNA 2827/4885SMN1; SMN2 1672/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | POLB 1926/4885LMNA 3152/4885SMN1; SMN2 3573/4885 |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | POLB 2825/4885LMNA 2364/4885SMN1; SMN2 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.